Background: Thrombosis in children with dilated and inflammatory cardiomyopathy is an unpredictable complication with potentially important morbidity.

Objective: To determine the prevalence, associated factors, management and outcomes of thrombosis in this setting.

Methods: Data were obtained from review of medical records. Factors associated with thrombosis and the impact on outcome were sought.

Results: From 1990 to 1998, 66 patients that presented with dilated cardiomyopathy were followed for a median interval of 1.4 years (range 0 to 9.79 years) from first presentation. Thrombosis was diagnosed in four patients at presentation and in four patients during follow-up. Thrombosis was noted in one additional patient at examination after death. The overall nine-year period prevalence of thrombosis was 14%. Anticoagulation was started at presentation in 31% of patients. The mean left ventricular ejection fraction at presentation was significantly lower in those given anticoagulation (19+/-8%) versus those who were not (32+/-15%; P < 0.001). The mean ejection fraction at presentation was similar in those patients with (25+/-10%) versus those without thrombosis (28+/-15%; P = 0.44). During follow-up, 11 patients died and seven underwent cardiac transplantation. Kaplan-Meier estimates of freedom from death or transplantation were 88% at three months, 81% at one year and 70% at five years. Survival free of transplantation was not affected by thrombosis.

Conclusions: Thrombosis is common in children with cardiomyopathy, can occur at any time in the patients' clinical course and is not related to clinical features or survival free of transplantation. The relevance and prevention of thrombosis in this setting remains unclear.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2560561PMC
http://dx.doi.org/10.1016/s0828-282x(06)70937-0DOI Listing

Publication Analysis

Top Keywords

thrombosis
10
management outcomes
8
outcomes thrombosis
8
thrombosis children
8
children cardiomyopathy
8
presentation patients
8
ejection fraction
8
fraction presentation
8
survival free
8
free transplantation
8

Similar Publications

Literature Commentary.

J Neuroophthalmol

January 2025

In this issue of JNO, Drs. Deborah I. Friedman and Mark L.

View Article and Find Full Text PDF

Distinct TYRO3 and PROS1 expression levels contribute to preeclampsia pathogenesis.

Histochem Cell Biol

January 2025

Departments of Obstetrics and Gynecology, School of Medicine, Akdeniz University, Antalya, Turkey.

Preeclampsia (PE) is a severe placental complication occurring after the 20th week of pregnancy. PE is associated with inflammation and an increased immune reaction against the fetus. TYRO3 and PROS1 suppress inflammation by clearing apoptotic cells.

View Article and Find Full Text PDF

Vascular Healing After Biodegradable Polymer Sirolimus-Eluting Versus Durable Polymer Everolimus-Eluting Stents in Chronic Total Occlusions.

Catheter Cardiovasc Interv

January 2025

State Key Laboratory of Frigid Zone Cardiovascular Diseases, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.

Background: Biodegradable polymer stents may reduce the risk of neoatherosclerosis and stent thrombosis. Limited data is available for biodegradable polymer sirolimus-eluting stent (BP-SES) and durable polymer drug-eluting stents (DP-EES) in chronic total occlusions (CTO).

Aim: This study was to evaluate healing patterns of BP-SES versus DP-EES in CTO at 3 and 13 months based on optical coherence tomography (OCT).

View Article and Find Full Text PDF

Objective: The objective of this study is to assess the feasibility of endovascular coiling combined with tissue glue embolism for the treatment of iliac arteriovenous fistula (AVF) secondary to deep vein thrombosis (DVT) of the lower extremities. In addition, we aim to summarize the treatment methods and enhance understanding of the disease.

Methods: This research analyzes the clinical data and medical imaging materials of 20 cases with iliac AVF secondary to lower extremity DVT, ranging from December 2014 to December 2020, at our hospital.

View Article and Find Full Text PDF

Optimizing the life of vascular access during follow-up.

J Cardiovasc Surg (Torino)

February 2025

Department of Vascular Surgery, ASST Settelaghi Universitary Teaching Hospital, University of Insubria, Varese, Italy.

Optimizing the longevity of vascular access in hemodialysis patients remains a critical aspect of patient care, given the significant role of arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) in enabling effective dialysis. Vascular access complications, such as stenosis, thrombosis, and cannulation-related damage, continue to challenge both the functionality and the sustainability of these access points. Recent advancements underscore the importance of a robust follow-up strategy, integrating clinical evaluations with diagnostic tools like color Doppler ultrasound (CDU) and emerging interventional approaches such as drug-coated balloon (DCB) angioplasty.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!